Pirfenidone Tablet, Film Coated
NDC Package 42385-925-90
Package Information
Pirfenidone tablets is pirfenidone is used to treat a certain lung disease called idiopathic pulmonary fibrosis (IPF). This formulation utilizes a tablet, film coated delivery system. Marketed by Laurus Labs Limited, this product is identified by NDC 42385-925 and is authorized under FDA application ANDA212722.
Identification & Billing
- RxCUI: 1592279 - pirfenidone 267 MG Oral Capsule
- RxCUI: 1868014 - pirfenidone 267 MG Oral Tablet
- RxCUI: 1868018 - pirfenidone 801 MG Oral Tablet
- RxCUI: 2606490 - pirfenidone 534 MG Oral Tablet
- RxCUI: 2606491 - {63 (pirfenidone 267 MG Oral Capsule) } Pack
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 42385 - Laurus Labs Limited
- 42385-925 - Pirfenidone
- 42385-925-90 - 90 TABLET, FILM COATED in 1 BOTTLE
- 42385-925 - Pirfenidone
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 42385-925-90 identifies a specific commercial package of 90 tablet, film coated in 1 bottle of Pirfenidone, a human prescription drug labeled by Laurus Labs Limited. This product is billed for "EA" each discreet unit and contains an estimated amount of 90 billable units per package. This tablet, film coated is formulated for oral use and contains pirfenidone as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Laurus Labs Limited on July 19, 2022. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Pirfenidone is used to treat a certain lung disease called idiopathic pulmonary fibrosis (IPF). This disease causes the lungs to get scarred and become stiff, making it hard to breathe. Pirfenidone may help slow down the worsening of your IPF.
How is this Laurus Labs Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 42385092590. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 90 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.